DIA: Woodcock, other top officials tout benefits of master protocols, want momentum to continue post-COVID

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyResearch, Design and Development